KROMATID Leverages ASGCT and ISCT Platforms to Advance Genomic Intelligence Strategy

KROMATID is using major cell and gene therapy conferences to spotlight its genomic integrity and cytogenetic analytics platforms for gene-edited cell therapies. Across multiple LinkedIn updates, the company detailed upcoming presentations at ASGCT and ISCT 2026 and framed these efforts as core to a broader genomic intelligence strategy.

At ASGCT, KROMATID is sponsoring a session on assessing genomic integrity in CRISPR-modified CAR-NK cells and presenting chromosome-scale benchmarks for genomic instability. These initiatives emphasize moving away from fragmented assay approaches toward integrated, decision-ready analytics that support biosafety and quality assessments.

KROMATID is also promoting a proprietary high-depth cytogenetic method as a cornerstone of what it calls the world’s first genomic intelligence platform. The approach aims to distinguish normal from abnormal structural variants against chromosome-level baselines, potentially improving risk evaluation from discovery through clinical development.

In parallel, the company is showcasing its KROMASURE platform at ISCT as a single-cell cytogenetic solution that can detect low-frequency off-target events, mosaic abnormalities, and complex rearrangements. KROMASURE is positioned as complementary to NGS, optical genome mapping, and arrays, with capabilities such as locus-specific tracking of edited targets and integration with sequencing data.

KROMATID’s use of the GIAB HG008-T tumor reference cell line to reveal structural complexity underscores its focus on regulatory-aligned genomic integrity testing. If adopted, these tools could become embedded in release testing and analytical workflows for cell and gene therapy developers, supporting recurring revenue from services and platform usage.

The company is also recruiting a Quality Assurance Specialist to bolster compliance and data standards as it builds out its genomic intelligence platform. This expansion in quality functions suggests preparation for increased operational volume and more regulated engagements, which may be important for partnerships with biopharma sponsors.

Overall, the week’s updates highlight KROMATID’s push to establish differentiated IP and infrastructure in genomic integrity analytics for advanced therapies. Successful scientific validation and conference visibility could enhance its competitive position, though specific commercial metrics and timelines remain undisclosed.